Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

OsteoArthritis and Therapy for Sleep (OATS)

1 april 2020 uppdaterad av: Michael Vitiello, University of Washington

Efficacy of Scalable CBT for Insomnia in Older Adults With Osteoarthritis Pain

Osteoarthritis (OA) pain affects 50 percent of older adults, more than half of whom also experience significant sleep disturbance. This randomized trial will determine whether a telephone-based cognitive behavioral treatment targeting insomnia in older adults with chronic severe OA-related insomnia and pain results in substantially greater reductions in insomnia severity and in related improvements in pain, fatigue, mood, quality of life and healthcare costs compared to telephone-delivered education (attention control) about insomnia. The trial will test an intervention that if demonstrated to have long term efficacy is scalable and has the potential for wide-scale deployment in healthcare systems.

Studieöversikt

Detaljerad beskrivning

Twenty-five percent of older adults experience significant osteoarthritis (OA)-related comorbid sleep disturbance. Insomnia is associated with substantial negative effects on function, mood, and medical resource utilization. Cognitive behavioral therapy for insomnia (CBT-I) is evidence based and has been shown to be efficacious in populations with a variety of comorbid conditions including OA-related chronic pain. However, in-person CBT interventions are unlikely to be widely deployable in healthcare systems. Telephone delivery has the advantage of giving patients access to personalized, efficacious CBT-I interventions from home, increasing generalizability, and outreach to minority, rural, and other underserved populations. Older (60+ yrs) primary care patients across Washington State will be screened for severe persistent OA-related insomnia and pain. Two hundred and seventy patients will be randomized to either CBT-I or an education only attention control (EOC). Each treatment will consist of six 20-30 minute telephone-based sessions over an eight week period. Pre-treatment, post-treatment (2 months and 12 month) assessments will include measures of sleep, pain, fatigue, mood, and quality of life. A cost effectiveness evaluation of the intervention will also be conducted. The proposed research will determine if telephone CBT-I improves OA insomnia and associated outcomes in a state-wide primary care population of older adults, and inform policy decisions about widespread dissemination of telephone CBT-I in this and related patient populations.

Studietyp

Interventionell

Inskrivning (Faktisk)

327

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Washington
      • Seattle, Washington, Förenta staterna, 98101
        • Kaiser Permanente Washington Research Institute

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

60 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 60+ with one or more health care visits for OA in the prior 3 years
  • Score of ≥6 on 4-item ISI at first screening and ≥11 on full ISI at second screening
  • Score of ≥9 on two items from the Brief Pain Inventory (BPI) asking about average pain intensity in the past 2 weeks (0-10 scale) and activity interference due to pain (0-10 scale) at first and second screening

Exclusion Criteria:

  • Not continuously enrolled at Group Health Cooperative for at least one year
  • Prior diagnosis of a primary sleep disorder: sleep apnea with an AHI/RDI score of 15+ or current use of a CPAP machine; periodic leg movement disorder; restless leg syndrome; sleep-wake cycle disturbance; or rapid eye movement behavior disorder
  • Diagnosis in the medical record of: rheumatoid arthritis, terminal disease, being considered for major surgery, active chemotherapy or radiation for cancer, or inpatient treatment for congestive heart failure within the previous 6 months
  • Diagnosis of dementia, use of acetylcholinesterase inhibitor and/or memantine for cognitive impairment, or cognitive impairment (>6 on the Short Orientation-Memory-Concentration Test)
  • Hearing or speech impairment sufficient to preclude participation in a telephone intervention

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Cognitive Behavioral Therapy
Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
Andra namn:
  • KBT-I
Aktiv komparator: Education Control
Education Only Control is delivered by trained sleep therapists in six telephone sessions.
Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
Andra namn:
  • EOC

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Insomnia Severity Index (ISI)
Tidsram: 12 months post baseline
A 7-item questionnaire that is a global measure of perceived insomnia severity. Items use a 5-point scale for total scores of 0-28, with >15 considered moderate severity.
12 months post baseline

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Insomnia Severity Index (ISI)
Tidsram: 2 months post baseline
A 7-item questionnaire that is a global measure of perceived insomnia severity.Items use a 5-point scale for total scores of 0-28, with >15 considered moderate severity.
2 months post baseline
Pittsburgh Sleep Quality Index (PSQI)
Tidsram: 2 months post baseline
Self-rating of overall sleep quality and disturbances using 7 sleep. components. PSQI global >5 is highly sensitive and specific for distinguishing good and poor sleepers.
2 months post baseline
Pittsburgh Sleep Quality Index (PSQI)
Tidsram: 12 months post baseline
Self-rating of overall sleep quality and disturbances using 7 sleep components. PSQI global >5 is highly sensitive and specific for distinguishing good and poor sleepers.
12 months post baseline
Brief Pain Inventory-short form (BPI-sf)
Tidsram: 2 months post baseline
A questionnaire to assess pain intensity and interference with activities. The BPI-sf rates pain intensity (4 items) and interference (7 items) from 0 to 10 and is validated for use in clinical trials with OA pain patients.
2 months post baseline
Brief Pain Inventory-short form (BPI-sf)
Tidsram: 12 months post baseline
A questionnaire to assess pain intensity and interference with activities. The BPI-sf rates pain intensity (4 items) and interference (7 items) from 0 to 10 and is validated for use in clinical trials with OA pain patients.
12 months post baseline
Flinders Fatigue Scale (FFS)
Tidsram: 2 months post baseline
A 7-item self-report questionnaire to measure fatigue level in a variety of situations.
2 months post baseline
Flinders Fatigue Scale (FFS)
Tidsram: 12 months post baseline
A 7-item self-report questionnaire to measure fatigue level in a variety of situations.
12 months post baseline
Patient Health Questionnaire (PHQ-8)
Tidsram: 2 months post baseline
4-point scale rates frequency of occurrence of 8 depressive symptoms.
2 months post baseline
Patient Health Questionnaire (PHQ-8)
Tidsram: 12 months post baseline
4-point scale rates frequency of occurrence of 8 depressive symptoms.
12 months post baseline
Sleep Hygiene Index (SHI)
Tidsram: 2 months post baseline
A 13-item scale that rates how often participants engage in specific sleep hygiene related behaviors, including continued adherence to CBT-I recommendations over time.
2 months post baseline
Sleep Hygiene Index (SHI)
Tidsram: 12 months post baseline
A 13-item scale that rates how often participants engage in specific sleep hygiene related behaviors, including continued adherence to CBT-I recommendations over time.
12 months post baseline
EuroQoL 5D (EQ-5D)
Tidsram: 2 months post baseline
Rates health status on five dimensions and overall health status from 0 to 100. The most widely used measure in clinical trials assessing general quality of life of OA patients.
2 months post baseline
EuroQoL 5D (EQ-5D)
Tidsram: 12 months post baseline
Rates health status on five dimensions and overall health status from 0 to 100. The most widely used measure in clinical trials assessing general quality of life of OA patients.
12 months post baseline
Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Tidsram: 2 months post baseline
A 24-item questionnaire rating pain, stiffness, and physical functioning in everyday activities. It is the most widely used condition-specific quality of life measure for arthritis cost-effectiveness studies.
2 months post baseline
Western Ontario and McMaster Universities Arthritis Index (WOMAC)
Tidsram: 12 months post baseline
A 24-item questionnaire rating pain, stiffness, and physical functioning in everyday activities. It is the most widely used condition-specific quality of life measure for arthritis cost-effectiveness studies.
12 months post baseline
Use of sleep and pain medications
Tidsram: Baseline through 24 months
NSAID, analgesic, sedative, and anti-depressant medication use.
Baseline through 24 months
Outpatient visits
Tidsram: Baseline through 24 months
The number of visits for OA, for sleep problems, and for visits irrespective of associated diagnosis.
Baseline through 24 months
Health care costs
Tidsram: Baseline through 24 months
The Group Health cost database will be used to estimate costs (from study entry to 24 months post enrollment) of ambulatory healthcare for all conditions, arthritis and sleep problems, and inpatient care.
Baseline through 24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Michael V Vitiello, PhD, University of Washington
  • Huvudutredare: Michael Von Korff, ScD, University of Washington
  • Huvudutredare: Kai Yeung, PhD, Kaiser Permanente

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 oktober 2016

Primärt slutförande (Faktisk)

1 december 2019

Avslutad studie (Förväntat)

1 november 2020

Studieregistreringsdatum

Först inskickad

19 oktober 2016

Först inskickad som uppfyllde QC-kriterierna

25 oktober 2016

Första postat (Uppskatta)

27 oktober 2016

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 april 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 april 2020

Senast verifierad

1 mars 2020

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera